Related Experiment Video

Updated: Jun 13, 2026

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

Do selective estrogen receptor modulators treat cervical precancer and cancer? Time to pool data from relevant trials

Philip E Castle

    International Journal of Cancer
    |May 18, 2010
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
    09:48

    An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

    Published on: September 12, 2019

    Related Experiment Videos

    Last Updated: Jun 13, 2026

    An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
    06:18

    An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

    Published on: August 13, 2019

    An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
    09:48

    An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

    Published on: September 12, 2019

    Related Concept Videos

    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against specific...
    Treatment Resistent Cancers02:56

    Treatment Resistent Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

    Articles linked to this work by shared authors, journal, and citation graph.

    Resistance to a Novel Clinical Trial Design for Multicancer Detection Tests: Experimental Investigation of Ambiguity Aversion.

    MDM policy & practice·2026

    Benefits and Harms of Immediate Versus Delayed Treatment of Cervical Intraepithelial Neoplasia Grade 2 : A Target Trial Emulation.

    Annals of internal medicine·2026

    Performance and reproducibility of Pylori DuoTect® in a high Helicobacter pylori prevalence Latin American population.

    Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi·2026

    Outcomes of the NCI cancer prevention fellowship program: a focus on mentorship within a multidisciplinary public health field.

    BMC medical education·2026

    Long-Term Prospective Cohort Study of Cervical Cancer Screening Using Triage of Women Who Are Human Papillomavirus-Positive With Dual Stain and Human Papillomavirus Genotyping.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

    Optimizing Cervical Cancer Screening by Age at Vaccination for Human Papillomavirus: Health and Resource Implications.

    Annals of internal medicine·2026

    Perioperative Rehabilitation and Initiation of Adjuvant Chemotherapy in Resected Non-Small Cell Lung Cancer.

    International journal of cancer·2026

    Incidence and Predictors of Immune-Related Hypothyroidism Under Pembrolizumab Across Gynecologic Malignancies and Melanoma: A Real-World Cohort Study.

    International journal of cancer·2026

    Comparative Effectiveness of Induction Chemotherapy Regimens in Pediatric and Adolescent Locally Advanced Nasopharyngeal Carcinoma: A Retrospective IPTW Analysis.

    International journal of cancer·2026

    Is Less More? An Update on Aspirin for Cancer Prevention in Lynch Syndrome From the Cancer Prevention Programme-CaPP.

    International journal of cancer·2026

    Early Cessation of Adjuvant Anti-PD-1 Therapy in Stage III and IV Melanoma.

    International journal of cancer·2026

    Germline Cancer Predisposition and De Novo Contributions in Pediatric Rhabdomyosarcoma: A Report From the Children's Oncology Group.

    International journal of cancer·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us